Legal Status Overview
Gray AreaGeorgia has no peptide-specific or "research chemical"-specific statute: a search of the Georgia State Board of Pharmacy's administrative rules and recent legislative activity turns up nothing that names peptides, BPC-157, TB-500, or research-use-only compounds as a distinct legal category. Instead, peptides sold in Georgia fall under the same general rules that govern any drug: the Georgia State Board of Pharmacy's compounding rules (Chapter 480-11), Georgia's 2023 amendment limiting non-patient-specific "office use" compounding to FDA-registered 503B outsourcing facilities, and the underlying federal FD&C Act framework (sections 503A/503B) that determines whether a compounded or unapproved peptide can lawfully be dispensed. FDA-approved peptide drugs such as semaglutide/tirzepatide-class GLP-1 medicines and prescription human growth hormone remain lawful only via a licensed prescriber and pharmacy, while compounds like BPC-157 and TB-500 have no FDA-approved human-use status and are typically sold only as "research use only" research chemicals.
Key Points
- Georgia's administrative code (Department 480, Georgia State Board of Pharmacy rules) contains no rule chapter or definition that names peptides or "research chemicals" as a distinct regulatory category. [1]
- Georgia's pharmaceutical compounding rules, found in Chapter 480-11 of the Georgia Administrative Code, regulate how any drug (including peptides) may be compounded by Georgia-licensed pharmacy personnel but do not single out peptides specifically. [2]
- Georgia amended its Pharmacy Act to limit non-patient-specific "office use" compounding -- the kind of bulk compounding used for products like compounded BPC-157 or GLP-1 blends -- to FDA-registered 503B outsourcing facilities, with narrow carve-outs for hospital-based pharmacies and physicians compounding for their own patients. [4]
- A Georgia-licensed pharmacy that compounds a peptide on a patient-specific prescription under the federal 503A pathway does not need any additional Georgia license beyond its existing pharmacy license, according to Georgia Board of Pharmacy guidance to compounders. [5]
- Compounded semaglutide and tirzepatide became widespread in Georgia during 2022-2024 specifically because FDA shortage designations temporarily allowed 503A and 503B pharmacies to compound versions of these GLP-1 drugs, a federal allowance rather than a Georgia-specific one. [6]
- Georgia residents cannot lawfully buy or import peptide drugs like compounded tirzepatide or semaglutide without a prescription; legitimate access requires a prescription issued by a licensed prescriber, including through Georgia-licensed telehealth platforms operating under the federal 503A framework. [7]
- No Georgia-specific statute, 2024-2025 legislative bill, or Attorney General guidance addressing peptides or research chemicals by name was found in legislative monitoring and bill-tracking sources covering the Georgia General Assembly's 2025-26 session. [8]
Peptide-by-peptide status in Georgia
| BPC-157 | BPC-157 has no Georgia-specific legal status and, under the general federal framework that Georgia defers to, it is not an FDA-approved or marketed drug, meaning it can only be sold lawfully in Georgia as an unapproved research-use-only compound rather than for human consumption. [9] |
|---|---|
| TB-500 (Thymosin Beta-4) | No Georgia statute addresses TB-500 specifically, so it is governed by the same general federal rule applied to BPC-157 -- it lacks FDA approval for human use and is therefore sold in Georgia, if at all, only as an unapproved research chemical rather than a legal prescription product. |
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are legal in Georgia only as FDA-approved prescription medicines (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) or as compounded versions prepared by a 503A or 503B pharmacy under a valid patient-specific prescription, not as over-the-counter research products. [6] |
| Human Growth Hormone (HGH/Somatropin) | Human growth hormone is not addressed by any Georgia-specific peptide statute and instead remains subject to the general prescription-drug and compounding rules administered by the Georgia State Board of Pharmacy, meaning lawful use in Georgia requires a valid prescription rather than direct consumer purchase. [2] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides in Georgia without a prescription?
No -- in Georgia, peptides that are FDA-approved drugs (such as GLP-1 medicines or prescription HGH) require a valid prescription from a licensed provider, and peptides without FDA approval, like BPC-157, have no legal over-the-counter human-use pathway and are typically sold only labeled as research chemicals not for human consumption. [9]
Does Georgia have its own research chemical or peptide law?
No -- Georgia has no statute or Board of Pharmacy rule that specifically names peptides or research chemicals as their own legal category; the Georgia State Board of Pharmacy's administrative code regulates compounding generally but does not single out peptides. [1]
Can a telehealth doctor prescribe compounded semaglutide or tirzepatide in Georgia?
Yes -- compounded tirzepatide and semaglutide are available to Georgia residents through licensed telehealth providers operating under the federal 503A compounding framework, provided there is a valid patient-specific prescription. [7]
What happens if I get caught selling or distributing unapproved peptides in Georgia?
Georgia has no peptide-specific penalty statute, so enforcement would flow through general Georgia pharmacy licensing law and federal FDA drug-misbranding/unapproved-new-drug enforcement rather than a dedicated peptide law; no Georgia-specific peptide enforcement action was identified in available records.
Is it legal to compound BPC-157 at a Georgia pharmacy for office use?
No -- Georgia law limits non-patient-specific "office use" compounding to FDA-registered 503B outsourcing facilities (with narrow exceptions for hospital pharmacies and physicians treating their own patients), so a standard Georgia 503A pharmacy compounding BPC-157 in bulk for office stock rather than an individual prescription would fall outside that carve-out. [4]